People

Search Language

中文(台灣) / Traditional Chinese | Use language selector above (below, on mobile) to search additional languages
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  • Search
  • Selected filters
  • x(sec enforcement)

1850 items matching filters

Search Results

Practice:

  • Technology & Innovation Sector
  • Capital Markets
  • Mergers & Acquisitions
  • 戰略諮詢
  • Corporate Governance
  • Continuing Disclosure
  • Technology Companies Group
  • Corporate & Venture Capital for the Life Sciences & HealthTech Sector
  • Japan
  • Renewable Energy
  • 機場與港口融資
  • Artificial Intelligence (AI)
  • UK National Security Group
  • Life Sciences & HealthTech
  • Energy
  • Fintech
  • Special Purpose Acquisition Companies (SPACs)

Edward Dyson Partner

London

He regularly advises on IPOs, direct listings, follow-ons, de-SPACs, reverse mergers and takeovers on UK, US and European stock exchanges, domestic and cross-border public and private M&A deals, venture capital, private and growth equity investments, debt financings, joint ventures, carve-outs, and restructurings, as well as on governance, disclosure, compliance and strategic advisory matters.

His broad industry experience includes working with clients in the AI and technology, healthcare and life sciences, logistics, retail, media, marketing, financial services, energy and natural resources sectors.

He was recently recognised in The Lawyer's Hot 100 2023, by Financial News as a Rising Star of Legal Services in Europe 2023 and Financial Times at its European Innovative Lawyer Awards 2023.

Practice:

  • Technology & Innovation Sector
  • Capital Markets
  • Mergers & Acquisitions
  • 戰略諮詢
  • Corporate Governance
  • Continuing Disclosure
  • Technology Companies Group
  • Corporate & Venture Capital for the Life Sciences & HealthTech Sector
  • Japan
  • Renewable Energy
  • 機場與港口融資
  • Artificial Intelligence (AI)
  • UK National Security Group
  • Life Sciences & HealthTech
  • Energy
  • Fintech
  • Special Purpose Acquisition Companies (SPACs)

Edward Dyson Partner

London

He regularly advises on IPOs, direct listings, follow-ons, de-SPACs, reverse mergers and takeovers on UK, US and European stock exchanges, domestic and cross-border public and private M&A deals, venture capital, private and growth equity investments, debt financings, joint ventures, carve-outs, and restructurings, as well as on governance, disclosure, compliance and strategic advisory matters.

His broad industry experience includes working with clients in the AI and technology, healthcare and life sciences, logistics, retail, media, marketing, financial services, energy and natural resources sectors.

He was recently recognised in The Lawyer's Hot 100 2023, by Financial News as a Rising Star of Legal Services in Europe 2023 and Financial Times at its European Innovative Lawyer Awards 2023.

Whitney Busch Alcorn Associate

Washington, D.C.

Whitney advises clients on a variety of litigation, enforcement, and regulatory matters.

Whitney Busch Alcorn Associate

Washington, D.C.

Whitney advises clients on a variety of litigation, enforcement, and regulatory matters.

Practice:

  • Finance Sector
  • 稅務
  • Corporate Tax
  • Public Finance Tax
  • Tax Advocacy
  • Finance
  • Structured Finance
  • Real Estate
  • Nonprofit Organizations
  • Residential Mortgage‐Backed Securities
  • International Tax
  • France
  • Derivatives
  • Charter School Finance
  • Asset‐Backed Securities
  • Banking & Finance
  • Fintech

Stephen Jackson Partner

Paris; New York

Steve is admitted in New York California, England and Wales, and Paris and his primary focus is on U.S. taxation of securitizations and re-securitizations, including collateralized debt and loan obligations, mortgage-backed securitizations, structured investment vehicles and other structured finance and financial markets transactions.

For over fifteen years, Steve has served as tax counsel to issuers and underwriters in numerous registered, agency and privately-placed CMBS and RMBS transactions (primary issuances and re-securitizations), involving performing loans and non-performing loans, as well as other mortgage-related asset classes, such as servicing advances and tax liens, and in securitizations involving other asset classes such as credit card and auto loan/lease receivables. Steve also provides tax advice in connection with whole loan purchase transactions, including leveraged and nonleveraged acquisitions, joint ventures involving mortgage assets and repo and warehouse financings for various asset classes. Steve also advises financial institutions on tax issues in connection with their role as servicer, trustee or securities administrator under various securitization programs, as well as with respect to FATCA.

Steve writes and lectures on finance and international related tax topics and also participates actively in the tax committee and other initiatives of the Structured Finance Association and other industry and bar-related organizations.

Practice:

  • Finance Sector
  • 稅務
  • Corporate Tax
  • Public Finance Tax
  • Tax Advocacy
  • Finance
  • Structured Finance
  • Real Estate
  • Nonprofit Organizations
  • Residential Mortgage‐Backed Securities
  • International Tax
  • France
  • Derivatives
  • Charter School Finance
  • Asset‐Backed Securities
  • Banking & Finance
  • Fintech

Stephen Jackson Partner

Paris; New York

Steve is admitted in New York California, England and Wales, and Paris and his primary focus is on U.S. taxation of securitizations and re-securitizations, including collateralized debt and loan obligations, mortgage-backed securitizations, structured investment vehicles and other structured finance and financial markets transactions.

For over fifteen years, Steve has served as tax counsel to issuers and underwriters in numerous registered, agency and privately-placed CMBS and RMBS transactions (primary issuances and re-securitizations), involving performing loans and non-performing loans, as well as other mortgage-related asset classes, such as servicing advances and tax liens, and in securitizations involving other asset classes such as credit card and auto loan/lease receivables. Steve also provides tax advice in connection with whole loan purchase transactions, including leveraged and nonleveraged acquisitions, joint ventures involving mortgage assets and repo and warehouse financings for various asset classes. Steve also advises financial institutions on tax issues in connection with their role as servicer, trustee or securities administrator under various securitization programs, as well as with respect to FATCA.

Steve writes and lectures on finance and international related tax topics and also participates actively in the tax committee and other initiatives of the Structured Finance Association and other industry and bar-related organizations.

450076

Practice:

  • Intellectual Property
  • Patents
  • Life Sciences & HealthTech
  • Supreme Court and Appellate

Irena Royzman, Ph.D. Partner

New York

With a Ph.D. in biology from MIT and the Whitehead Institute, where she was a NSF fellow, Irena represents plaintiffs and defendants in their most complex pharmaceutical and biotech patent cases. Over the last 20 years, pharmaceutical and biotechnology innovators have relied on Irena again and again for cases involving small molecules, biologics, recombinant DNA technology, gene therapy, gene editing, manufacturing processes, formulations and drug-eluting medical devices, including numerous multi-billion dollar cases involving many of the world’s best-selling drugs.

Irena has significant experience in litigation under the Hatch-Waxman Act (ANDA and 505(b)(2) actions) and the Biologics Price Competition and Innovation Act (BPCIA), as well as inter partes review (IPR) proceedings, license disputes and matters with parallel ex-U.S. litigation and proceedings in foreign patent offices. Irena also helps life sciences companies and organizations develop the law in the most important cases for the biopharma industry. She has been principal counsel on numerous amicus briefs to the United States Supreme Court and the Federal Circuit in key biopharma cases.

For plaintiffs, Irena has successfully defended generic challenges to patents protecting blockbuster medical therapies, including multi-billion dollar cancer, antiviral, diabetes and anti-psychotic drugs, including recently obtaining attorneys’ fees in a hard-fought ANDA action. She also represents innovators in biosimilar litigation from its outset, including in some of the first cases under the BPCIA involving antibodies. Irena also represents clients in innovator vs innovator disputes. For defendants, she defeated a $530 million claim of patent infringement of a competitor’s biotech patent, obtaining dismissal of all claims and discovery sanctions against the patent owner. In another high-stakes case, she obtained summary judgment of noninfringement and exclusion of plaintiff’s experts under Daubert as well as a full award of attorneys’ fees. A registered patent attorney, Irena also handles inter partes review (IPR) proceedings. For patent owners, she has obtained denial of IPR for patents protecting blockbuster drugs and has leveraged IPR for defendants to obtain freedom to operate.

Irena also coordinates U.S. proceedings with parallel ex-U.S. litigation and proceedings in foreign patent offices, recently obtaining freedom to operate for a biotech innovator’s gene therapy. She provides strategic counseling in biologics and pharmaceuticals and advises clients on their IP portfolios and transactions. Irena also represents clients in high-stakes license disputes involving biotech patents, and, in a dispute concerning the use of a recombinant protein as an enzyme replacement therapy, obtained one of the largest settlement awards over the life of the contract.

Chambers USA has recognized Irena as a leading lawyer in intellectual property, where clients have described her as “excellent,” “knowledgeable, aggressive,” “knows the science forward and backward” and “an incredibly smart lawyer.” Benchmark Litigation named her one of the “Top 250 Women in Litigation” for the last eight years and a litigation star in intellectual property. Irena was also named to the Crain’s New York Business list of “Notable Women in Law.” She is also recognized as a leading lawyer by Legal 500. Irena writes and lectures widely on biopharma patent issues and biosimilar litigation. Irena also is frequently quoted on patent-related issues, including in the Washington Post, Financial Times, Nature Biotechnology, Bloomberg and Pink Sheet.

450076

Practice:

  • Intellectual Property
  • Patents
  • Life Sciences & HealthTech
  • Supreme Court and Appellate

Irena Royzman, Ph.D. Partner

New York

With a Ph.D. in biology from MIT and the Whitehead Institute, where she was a NSF fellow, Irena represents plaintiffs and defendants in their most complex pharmaceutical and biotech patent cases. Over the last 20 years, pharmaceutical and biotechnology innovators have relied on Irena again and again for cases involving small molecules, biologics, recombinant DNA technology, gene therapy, gene editing, manufacturing processes, formulations and drug-eluting medical devices, including numerous multi-billion dollar cases involving many of the world’s best-selling drugs.

Irena has significant experience in litigation under the Hatch-Waxman Act (ANDA and 505(b)(2) actions) and the Biologics Price Competition and Innovation Act (BPCIA), as well as inter partes review (IPR) proceedings, license disputes and matters with parallel ex-U.S. litigation and proceedings in foreign patent offices. Irena also helps life sciences companies and organizations develop the law in the most important cases for the biopharma industry. She has been principal counsel on numerous amicus briefs to the United States Supreme Court and the Federal Circuit in key biopharma cases.

For plaintiffs, Irena has successfully defended generic challenges to patents protecting blockbuster medical therapies, including multi-billion dollar cancer, antiviral, diabetes and anti-psychotic drugs, including recently obtaining attorneys’ fees in a hard-fought ANDA action. She also represents innovators in biosimilar litigation from its outset, including in some of the first cases under the BPCIA involving antibodies. Irena also represents clients in innovator vs innovator disputes. For defendants, she defeated a $530 million claim of patent infringement of a competitor’s biotech patent, obtaining dismissal of all claims and discovery sanctions against the patent owner. In another high-stakes case, she obtained summary judgment of noninfringement and exclusion of plaintiff’s experts under Daubert as well as a full award of attorneys’ fees. A registered patent attorney, Irena also handles inter partes review (IPR) proceedings. For patent owners, she has obtained denial of IPR for patents protecting blockbuster drugs and has leveraged IPR for defendants to obtain freedom to operate.

Irena also coordinates U.S. proceedings with parallel ex-U.S. litigation and proceedings in foreign patent offices, recently obtaining freedom to operate for a biotech innovator’s gene therapy. She provides strategic counseling in biologics and pharmaceuticals and advises clients on their IP portfolios and transactions. Irena also represents clients in high-stakes license disputes involving biotech patents, and, in a dispute concerning the use of a recombinant protein as an enzyme replacement therapy, obtained one of the largest settlement awards over the life of the contract.

Chambers USA has recognized Irena as a leading lawyer in intellectual property, where clients have described her as “excellent,” “knowledgeable, aggressive,” “knows the science forward and backward” and “an incredibly smart lawyer.” Benchmark Litigation named her one of the “Top 250 Women in Litigation” for the last eight years and a litigation star in intellectual property. Irena was also named to the Crain’s New York Business list of “Notable Women in Law.” She is also recognized as a leading lawyer by Legal 500. Irena writes and lectures widely on biopharma patent issues and biosimilar litigation. Irena also is frequently quoted on patent-related issues, including in the Washington Post, Financial Times, Nature Biotechnology, Bloomberg and Pink Sheet.

Practice:

  • Financial & Fintech Advisory
  • Strategic Advisory & Government Enforcement (SAGE)
  • Fintech
  • Cyber, Privacy & Data Innovation
  • Mergers & Acquisitions
  • Blockchain & Digital Assets
  • Japan
  • China

Nathaniel Reisenburg Managing Associate

New York

Nathaniel counsels banks, blockchain exchanges, cryptocurrency issuers, financial institutions, technology companies, money transmitters, online gaming platforms, payment processors, and private equity firms. His practice includes services related to anti-money laundering, data collection and processing, internal investigations and risks assessments, money transmitter licensing, blockchain token offerings, mergers and acquisitions, money transmitter licensing, venture capital financing activities, and general corporate matters.

Following law school, Nathaniel co-founded a legaltech company in Japan, and developed the initial machine learning models and a front end used for an initial product offering. Nathaniel has since leveraged his development experience to communicate with and advise blockchain and machine learning ventures. In addition, Nathaniel has also lectured at Peking University in China, teaching constitutional law and an introductory class on U.S. legal principles, giving Nathaniel a unique perspective into the Chinese market.

Prior to joining Orrick’s New York office, he was an associate at the firm's Tokyo office. In addition, prior to law school, Nathaniel served for four years in the Canadian Army as an enlisted soldier tasked to conduct armored reconnaissance.  

Practice:

  • Financial & Fintech Advisory
  • Strategic Advisory & Government Enforcement (SAGE)
  • Fintech
  • Cyber, Privacy & Data Innovation
  • Mergers & Acquisitions
  • Blockchain & Digital Assets
  • Japan
  • China

Nathaniel Reisenburg Managing Associate

New York

Nathaniel counsels banks, blockchain exchanges, cryptocurrency issuers, financial institutions, technology companies, money transmitters, online gaming platforms, payment processors, and private equity firms. His practice includes services related to anti-money laundering, data collection and processing, internal investigations and risks assessments, money transmitter licensing, blockchain token offerings, mergers and acquisitions, money transmitter licensing, venture capital financing activities, and general corporate matters.

Following law school, Nathaniel co-founded a legaltech company in Japan, and developed the initial machine learning models and a front end used for an initial product offering. Nathaniel has since leveraged his development experience to communicate with and advise blockchain and machine learning ventures. In addition, Nathaniel has also lectured at Peking University in China, teaching constitutional law and an introductory class on U.S. legal principles, giving Nathaniel a unique perspective into the Chinese market.

Prior to joining Orrick’s New York office, he was an associate at the firm's Tokyo office. In addition, prior to law school, Nathaniel served for four years in the Canadian Army as an enlisted soldier tasked to conduct armored reconnaissance.  

Practice:

  • Supreme Court and Appellate

Lauren Weber Senior Associate

Seattle

Lauren represents clients in high-stakes appeals, with a focus on patent litigation. Lauren also joins trial teams as embedded appellate counsel to guide the legal strategy with an eye toward appeal and draft important briefs. She has argued in the Federal Circuit on behalf of a leading video-game developer, where she secured affirmance of the PTAB's decision striking down every claim of a competitor's patent, and in the Ninth Circuit, where she won relief from removal for a client seeking asylum. She has co-authored dozens of appellate briefs, as well as briefs in the U.S. Supreme Court at both the certiorari and merits stages. Lauren also has an active pro bono practice focused on immigration matters and civil rights.

Before joining Orrick, Lauren served as a law clerk to Judge Susan P. Graber of the U.S. Court of Appeals for the Ninth Circuit and Judge John R. Blakey of the U.S. District Court for the Northern District of Illinois. Lauren graduated summa cum laude from the University of Wisconsin Law School, where she received the Salmon Dalberg Award for outstanding member of the graduating class and was a Managing Editor for the Wisconsin Law Review. Before law school, Lauren worked for a major software company in the healthcare industry.

Practice:

  • Supreme Court and Appellate

Lauren Weber Senior Associate

Seattle

Lauren represents clients in high-stakes appeals, with a focus on patent litigation. Lauren also joins trial teams as embedded appellate counsel to guide the legal strategy with an eye toward appeal and draft important briefs. She has argued in the Federal Circuit on behalf of a leading video-game developer, where she secured affirmance of the PTAB's decision striking down every claim of a competitor's patent, and in the Ninth Circuit, where she won relief from removal for a client seeking asylum. She has co-authored dozens of appellate briefs, as well as briefs in the U.S. Supreme Court at both the certiorari and merits stages. Lauren also has an active pro bono practice focused on immigration matters and civil rights.

Before joining Orrick, Lauren served as a law clerk to Judge Susan P. Graber of the U.S. Court of Appeals for the Ninth Circuit and Judge John R. Blakey of the U.S. District Court for the Northern District of Illinois. Lauren graduated summa cum laude from the University of Wisconsin Law School, where she received the Salmon Dalberg Award for outstanding member of the graduating class and was a Managing Editor for the Wisconsin Law Review. Before law school, Lauren worked for a major software company in the healthcare industry.